Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma.
Publication
, Conference
Duvic, M; Foss, FM; Olsen, EA; Forero-Torres, A; Bennett, JC; Bantia, S; Kilpatrick, JM
Published in: BLOOD
November 16, 2004
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2004
Volume
104
Issue
11
Start / End Page
683A / 683A
Location
San Diego, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
46th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Duvic, M., Foss, F. M., Olsen, E. A., Forero-Torres, A., Bennett, J. C., Bantia, S., & Kilpatrick, J. M. (2004). Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. In BLOOD (Vol. 104, pp. 683A-683A). San Diego, CA: AMER SOC HEMATOLOGY.
Duvic, M., F. M. Foss, E. A. Olsen, A. Forero-Torres, J. C. Bennett, S. Bantia, and J. M. Kilpatrick. “Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma.” In BLOOD, 104:683A-683A. AMER SOC HEMATOLOGY, 2004.
Duvic M, Foss FM, Olsen EA, Forero-Torres A, Bennett JC, Bantia S, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. In: BLOOD. AMER SOC HEMATOLOGY; 2004. p. 683A-683A.
Duvic, M., et al. “Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma.” BLOOD, vol. 104, no. 11, AMER SOC HEMATOLOGY, 2004, pp. 683A-683A.
Duvic M, Foss FM, Olsen EA, Forero-Torres A, Bennett JC, Bantia S, Kilpatrick JM. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. BLOOD. AMER SOC HEMATOLOGY; 2004. p. 683A-683A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2004
Volume
104
Issue
11
Start / End Page
683A / 683A
Location
San Diego, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
46th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology